News Category
Onco-Innovations has reported key preclinical progress for its PNKP inhibitor ONC010, including high-purity API manufacturing and plans for a First-in...
VERAXA Biotech strengthens its leadership with the appointment of Raju Willener as CFO, bringing extensive financial expertise to support its BiTAC pl...
BioVersys will showcase its anti-MDR bacteria pipeline at the H.C. Wainwright conference, highlighting progress in addressing antimicrobial resistance...
OS Therapies is set to present at the Moody Capital conference amid critical regulatory milestones for its lead candidate OST-HER2, potentially reshap...
A Swiss-led preclinical study reveals that administering immunotherapy before surgery significantly improves glioblastoma treatment outcomes, potentia...
Tonix Pharmaceuticals' participation in the Cantor 2026 Global Healthcare Conference underscores its commercial-stage evolution and the strategic impo...
NurExone Biologic's upcoming presentation at a major life sciences conference highlights its exosome-based therapeutic platform and U.S. expansion str...
CNS Pharmaceuticals' Chief Business Officer details the company's strategic approach to in-licensing and acquisitions in oncology and neurology, highl...
The launch of the third InnoHK research cluster at Hong Kong Science Park positions Hong Kong as a global hub for sustainable development, energy, adv...
Quantum BioPharma receives a 'Buy' rating and $8.00 price target from Rodman & Renshaw, highlighting the potential of its lead candidate Lucid-MS for ...
NanoViricides is progressing its measles treatment NV-387 toward a Phase II trial as measles cases rise, leveraging strong preclinical data and FDA de...
TransCode Therapeutics' lead candidate TTX-MC138 demonstrated significant survival benefits in a preclinical breast cancer bone metastasis model, supp...
Oragenics provides updates on its Phase IIa trial for ONP-002, FDA interactions, and NYSE American listing compliance, highlighting progress and chall...
Creative Biolabs has updated its in vivo CAR-T development solutions, offering viral and non-viral delivery options to help researchers overcome chall...
Lonza's appointment of Samanta Cimitan as its first Chief Commercial Officer underscores its commitment to unifying customer engagement and accelerati...
Heidelberg Pharma and Huadong Medicine received Chinese regulatory approval to test the ADC HDP-101 in combination therapies for relapsed/refractory m...
A new study published in Critical Care Medicine demonstrates that VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality and re...
Monod Bio's licensing of its AI-designed LuxSit luciferase and NovoBodies to SignalChem Biotech enhances custom assay services, broadening access to a...
GeoVax Labs secures approximately $3.6 million through a warrant inducement transaction, providing working capital to advance its clinical-stage vacci...
Lakewood-Amedex Biotherapeutics becomes a B2i Digital Featured Company, spotlighting its Bisphosphocin class and upcoming Phase 2a trial for infected ...
Citius Pharmaceuticals transitions to a commercial-stage biopharma with LYMPHIR generating revenue, while its late-stage pipeline, including Mino-Lok ...
Annovis Bio's upcoming webinar will detail progress on its Phase 3 Alzheimer's trial and long-term safety studies, underscoring its commitment to addr...
A new study suggests that a personalized mRNA vaccine derived from a patient's tumor can prevent melanoma recurrence for years, offering hope for dura...
Creative Biolabs will host a webinar on September 1, 2026, featuring Dr. Greg M. Delgoffe to discuss modeling T cell dysfunction in tumor microenviron...
Synthesis Peptides now provides third-party Certificates of Analysis for all its research peptides, enhancing transparency and reliability for scienti...
A novel T cell therapy shows promise in treating recurrent glioblastoma, potentially offering new hope for a disease with limited options.
VERAXA Biotech and Secarna Pharmaceuticals announced initial positive results from their collaboration on antibody oligonucleotide conjugates, demonst...
VERAXA Biotech's VXA-222 bispecific antibody-drug conjugate program moves to preclinical validation, strengthening its oncology pipeline and intellect...
Scinai Immunotherapeutics' first-half 2026 results show increased revenue and a strategic expansion of its CDMO services, positioning the company for ...
A new composite scoring system combining day 7 biopsy findings with blood test trends identifies that most early liver rejection episodes resolve with...
VERAXA Biotech's receipt of favorable Scientific Advice from Germany's Paul-Ehrlich-Institute de-risks the clinical development path for its lead BiTA...
VERAXA Biotech is advancing its antibody-based cancer therapies through its proprietary BiTAC platform, with recent progress on its VXA-222 bispecific...
Onco-Innovations' potential acquisition of an exclusive option on Ifowonco's oral LAG-3 inhibitor program could position the company at the forefront ...
Creative Biolabs has expanded its complement assay services, providing researchers with advanced tools to evaluate complement-targeted therapeutics an...
Quantum BioPharma's Lucid-MS targets myelin degradation, offering a novel approach to treating multiple sclerosis that may address disability progress...
Silo Pharma's receipt of a Canadian patent allowance for SPC-15 strengthens its global IP position and supports its strategy to develop a novel intran...
Quantum BioPharma's Lucid-MS, a novel myelin-protecting therapy for multiple sclerosis, gains FDA clearance for phase 2 trials, highlighting a shift t...
Regentis Biomaterials received a Japanese Notice of Allowance for its solvent-free manufacturing process, strengthening its IP portfolio and supportin...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize its BiTAC platform, potentially reducing development risks and reviving abandoned drug...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize dual-target cancer therapies, potentially reviving abandoned drug targets and improvin...
Nanox Imaging's subsidiary signs an exclusive UK reseller agreement for its AI bone health solution, HealthOST, following NICE recommendation, marking...
Helix BioPharma has appointed Dr. Markus Loeffler as Chief Medical Officer to lead its clinical programs, including a planned Phase Ib/II trial of L-D...
Quantum BioPharma's significant cost reduction and FDA approval for its Phase 2 trial of Lucid-MS for progressive multiple sclerosis underscore its st...
Regentis Biomaterials is progressing its GelrinC cartilage repair product through U.S. pivotal trials and European commercialization simultaneously, w...
Helix BioPharma Corp. reshapes its board to align with governance and capital markets needs, appointing CEO Thomas Mehrling as director following Janu...
Onco-Innovations is progressing its precision oncology program ONC010, a nanoparticle-encapsulated PNKP inhibitor, through key manufacturing and metab...
A study from the University of Manchester reveals that a previously underappreciated group of immune cells is essential for mobilizing and sustaining ...
Quantum BioPharma reports a 53% reduction in Q2 operating expenses and FDA approval to proceed with Phase 2 trials for Lucid-MS in progressive multipl...
